AstraZeneca
↗Cambridge, United Kingdom
AstraZeneca is a multinational biopharmaceutical company formed in 1999 through the merger of Swedish Astra AB and British Zeneca Group. Headquartered in Cambridge, United Kingdom, the company is one of the top 10 global pharmaceutical companies with a strong focus on oncology, cardiovascular, renal & metabolism, respiratory & immunology, and rare disease therapeutics. AstraZeneca operates across 6 continents with approximately 78,000-94,300 employees and is pursuing an ambitious 'Ambition 2030' strategy targeting $80 billion in total revenue by 2030, with approximately 70% coming from new or recently launched medicines. The company has established itself as an oncology powerhouse with innovative approaches including ADCs, cell therapies, radioconjugates, and immuno-oncology platforms.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Big Pharma - Diversified Portfolio
SIZE & FINANCIALS
Employees:10000+
Revenue:$54.07B (2024)
Founded:1999
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ, LSE
Ticker:AZN
Market Cap:$279.6B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Pre-registration|Commercial
Lead Drug Stage:Multiple Phase III and pre-registration programs (16 positive Phase III trials in 2025)
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-drug conjugates (ADC), Bispecific antibodies, Multispecific antibodies, Cell therapy (CAR-T, TCR-T), Radioconjugates, PROTACs, Molecular glues
Active Trials:109
Trial Phases:Phase 3: 38
FDA Approvals:9
CORPORATE STRUCTURE
Subsidiaries:EsoBiotec (acquired 2025 for up to $1B), MedImmune
Key Partnerships:Alteogen - exclusive license for ALT-B4 (Hybrozyme hyaluronidase platform for SC oncology formulations), Cambridge Antibody Technology heritage - antibody discovery platform, Speke manufacturing partnership with Philadelphia sister site for influenza vaccine
COMPETITION
Position:Leader
Competitors:Pfizer, Merck & Co, Roche, Bristol-Myers Squibb (BMS), Johnson & Johnson, Novartis, GSK (GlaxoSmithKline), Boehringer Ingelheim
LEADERSHIP
Key Executives:
Pascal Soriot - Chief Executive Officer and Executive Director
Aradhana Sarin - Chief Financial Officer and Director
Marc Dunoyer - Executive
Helen MacPhee - Executive
Scientific Founders:Astra AB (founded 1913 by 400 doctors and apothecaries in Södertälje, Sweden), Zeneca Group (formed 1993 from ICI pharmaceutical demerger)
Board Members:Michel Demaré (Non-Executive Chair), Pascal Soriot (Chief Executive Officer), Philip Broadley (Senior Independent Non-Executive Director), Tony Mok (Non-Executive Director), Rene Haas (Non-Executive Director), Birgit Conix (Non-Executive Director)
LINKS
Website:astrazeneca.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AstraZeneca. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.